A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLC
Trial details
- Registry ID
- NCT06908304
- Phase
- Phase 3
The FDA approved Cemiplimab (LIBTAYO®) on 28 Sep 2018.
Drug identity checked against registry records
Also recorded as LIBTAYO®; Libtayo
| Trial | Sponsor | Phase | Status | Primary completion |
|---|---|---|---|---|
| A Phase III Study With THIO + Cemiplimab vs Chemotherapy as 3rd Line Treatment in Advanced/Metastatic NSCLCNCT06908304 | Maia Biotechnology | Phase 3 | Recruiting | 2027-07-31Estimated |
| THIO Sequenced With Cemiplimab in Advanced NSCLCNCT05208944 | Maia Biotechnology | Phase 2 | Active not recruiting | 2027-09-30Estimated |
| Study Evaluating Cemiplimab Alone and Combined With RP1 in Treating Advanced Squamous Skin CancerNCT04050436 | Replimune, Inc. | Phase 2 | Active not recruiting | 2025-09Estimated |
| Date as reported | Drug / company | Event | Condition | Evidence |
|---|---|---|---|---|
| 2018-09-28Day | Cemiplimab | FDA original application approvalFDA approval decision | Not specified | Open original sourceRead source excerpt{"application_number": "BLA761097", "applicant_as_listed_by_fda": "REGENERON PHARMACEUTICALS", "brand_names": ["LIBTAYO"], "active_ingredients": ["CEMIPLIMAB-RWLC"], "submission_type": "ORIG", "submission_number": "1", "submission_status": "AP", "submission_status_date": "20180928", "matched_on": "registry alias equals FDA brand name and drug name is its active ingredient"} First seen: 06 Oct 2026 · Evidence last checked: 06 Oct 2026 |